Insmed Incorporated (NASDAQ:INSM) is Hood River Capital Management LLC's 10th Largest Position

Hood River Capital Management LLC lifted its position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 3.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,525,628 shares of the biopharmaceutical company's stock after acquiring an additional 53,073 shares during the quarter. Insmed accounts for approximately 1.6% of Hood River Capital Management LLC's investment portfolio, making the stock its 10th biggest holding. Hood River Capital Management LLC owned approximately 0.85% of Insmed worth $105,329,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in INSM. Jennison Associates LLC grew its holdings in shares of Insmed by 0.6% in the fourth quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company's stock valued at $53,424,000 after purchasing an additional 4,560 shares during the period. Capital CS Group LLC acquired a new stake in Insmed during the 4th quarter worth approximately $586,000. Tidal Investments LLC grew its stake in Insmed by 447.0% during the 3rd quarter. Tidal Investments LLC now owns 24,102 shares of the biopharmaceutical company's stock worth $1,759,000 after purchasing an additional 19,696 shares in the last quarter. Harbor Capital Advisors Inc. lifted its stake in Insmed by 237.1% in the fourth quarter. Harbor Capital Advisors Inc. now owns 59,600 shares of the biopharmaceutical company's stock worth $4,115,000 after acquiring an additional 41,918 shares during the last quarter. Finally, abrdn plc grew its stake in shares of Insmed by 159.5% during the fourth quarter. abrdn plc now owns 289,653 shares of the biopharmaceutical company's stock worth $19,998,000 after purchasing an additional 178,041 shares in the last quarter.

Wall Street Analyst Weigh In

INSM has been the subject of a number of research reports. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $100.00 target price on shares of Insmed in a report on Wednesday, March 19th. Truist Financial lifted their price target on Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Bank of America increased their target price on Insmed from $92.00 to $96.00 and gave the company a "buy" rating in a report on Thursday, March 20th. JPMorgan Chase & Co. lifted their target price on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research note on Friday, February 7th. Finally, Wells Fargo & Company increased their price objective on shares of Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $94.00.

Insmed Trading Up 2.5 %

Shares of Insmed stock opened at $71.24 on Wednesday. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91. The business's 50 day moving average is $74.99 and its 200-day moving average is $73.58. The stock has a market cap of $12.95 billion, a P/E ratio of -12.74 and a beta of 1.07.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Equities research analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Insmed news, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $77.94, for a total transaction of $1,461,375.00. Following the completion of the sale, the chief executive officer now directly owns 379,534 shares in the company, valued at $29,580,879.96. The trade was a 4.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Sara Bonstein sold 18,322 shares of Insmed stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the transaction, the chief financial officer now directly owns 118,863 shares in the company, valued at $9,545,887.53. This trade represents a 13.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 471,797 shares of company stock valued at $37,621,239. 3.00% of the stock is owned by company insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.